Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, CEP: 31270-901, Brazil.
Braz J Microbiol. 2020 Sep;51(3):1439-1445. doi: 10.1007/s42770-020-00247-8. Epub 2020 Mar 6.
Porcine circovirus 2 (PCV2) infections are related to a number of syndromes and clinical manifestations, generally known as Porcine circovirus-associated diseases, which are related to losses in the swine industry. There are commercially available vaccines and new vaccines being tested, however, persistency of the PCV2 as an important pig pathogen, and the growing number of affected farms in different countries have suggested that there is room for vaccine improvement. In this study, we describe the construction and testing of a recombinant live vaccine based on a modified Vaccinia virus Ankara (MVA) vector expressing the PCV2b capsid protein (CAP). Using a two-dose homologous vaccination regimen, in mice, we demonstrated that the vaccine induced high titers of anti-PCV2 antibodies. The vaccine is stable upon lyophilization, and, together with the good immunogenicity potential observed, the results support further evaluation of the MVA-CAP vaccine in the target species.
猪圆环病毒 2 型（PCV2）感染与多种综合征和临床表现有关，通常被称为猪圆环病毒相关疾病，这些疾病与养猪业的损失有关。目前已有市售疫苗和正在测试的新型疫苗，但 PCV2 作为一种重要的猪病原体的持续性，以及不同国家受感染农场的数量不断增加，表明疫苗还有改进的空间。在本研究中，我们描述了一种基于改良安卡拉痘苗病毒（MVA）载体表达 PCV2b 衣壳蛋白（CAP）的重组活疫苗的构建和测试。使用两剂同源疫苗接种方案，我们在小鼠中证明了该疫苗能够诱导高水平的抗 PCV2 抗体。该疫苗在冻干后稳定，加上观察到的良好免疫原性潜力，这些结果支持进一步在目标物种中评估 MVA-CAP 疫苗。
